{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:35:11Z","timestamp":1782239711262,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01687-y","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:13:35Z","timestamp":1755843215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of combination chelation with deferasirox and deferiprone in children with beta-thalassemia major: an audit from a unit in the developing world"],"prefix":"10.1007","volume":"25","author":[{"given":"Vinson","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1687_CR1","volume-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia","author":"MD Cappellini","year":"2014","unstructured":"Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia. 3rd ed. Cyprus: Thalassemia International Federation Publication; 2014.","edition":"3"},{"issue":"1","key":"1687_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/nyas.13088","volume":"1368","author":"JL Kwiatkowski","year":"2016","unstructured":"Kwiatkowski JL. Current recommendations for chelation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):107\u201314.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"1687_CR3","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1016\/j.clinthera.2015.10.001","volume":"37","author":"C Borgna-Pignatti","year":"2015","unstructured":"Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Ther. 2015;37(12):2866\u201377.","journal-title":"Clin Ther"},{"issue":"5","key":"1687_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","volume":"154","author":"E Voskaridou","year":"2011","unstructured":"Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol. 2011;154(5):654\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"1687_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5045\/br.2014.49.1.72","volume":"49","author":"S Alavi","year":"2014","unstructured":"Alavi S, Sadeghi E, Ashenagar A. Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload. Blood Res. 2014;49(1):72\u20133.","journal-title":"Blood Res"},{"issue":"9","key":"1687_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/pbc.25533","volume":"62","author":"S Totadri","year":"2015","unstructured":"Totadri S, Bansal D, Bhatia P, et al. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with \u03b2-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62(9):1592\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1687_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13312-016-0821-4","volume":"53","author":"S Gomber","year":"2016","unstructured":"Gomber S, Jain P, Sharma S, et al. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatr. 2016;53(3):207\u201310.","journal-title":"Indian Pediatr"},{"key":"1687_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","volume":"148","author":"K Farmaki","year":"2010","unstructured":"Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466\u201375.","journal-title":"Br J Haematol"},{"key":"1687_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","volume":"145","author":"A Maggio","year":"2009","unstructured":"Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone desferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245\u201354.","journal-title":"Br J Haematol"},{"key":"1687_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00277-005-0075-z","volume":"85","author":"S Daar","year":"2006","unstructured":"Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315\u20139.","journal-title":"Ann Hematol"},{"key":"1687_CR11","first-page":"1309","volume":"90","author":"R Origa","year":"2005","unstructured":"Origa R, Bina P, Agus A. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologia. 2005;90:1309\u201314.","journal-title":"Haematologia"},{"key":"1687_CR12","first-page":"505","volume":"4","author":"M Morado","year":"2000","unstructured":"Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospec Cohort Stud Hematol. 2000;4:505.","journal-title":"Prospec Cohort Stud Hematol"},{"issue":"1","key":"1687_CR13","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2019.030","volume":"11","author":"F Pilo","year":"2019","unstructured":"Pilo F, Angelucci E. Iron toxicity and hemopoietic cell transplantation: time to change the paradigm. Mediterr J Hematol Infect Dis. 2019;11(1): e2019030.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1687_CR14","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","volume":"336","author":"NF Olivieri","year":"1990","unstructured":"Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferoxamine in iron-loaded patients. Lancet. 1990;336:1275\u20139.","journal-title":"Lancet"},{"key":"1687_CR15","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood.V83.8.2329.2329","volume":"83","author":"AF Collins","year":"1994","unstructured":"Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329\u201333.","journal-title":"Blood"},{"issue":"4","key":"1687_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12098-020-03442-5","volume":"88","author":"RR DivakarJose","year":"2021","unstructured":"DivakarJose RR, Delhikumar CG, Kumar R, et al. Efficacy and safety of combined oral chelation with deferiprone and deferasirox on iron overload in transfusion dependent children with thalassemia\u2014a prospective observational study. Indian J Pediatr. 2021;88(4):330\u20135.","journal-title":"Indian J Pediatr"},{"issue":"5","key":"1687_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ejh.12507","volume":"95","author":"MS Elalfy","year":"2015","unstructured":"Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95(5):411\u201320. https:\/\/doi.org\/10.1111\/ejh.12507.","journal-title":"Eur J Haematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01687-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01687-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01687-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:47:45Z","timestamp":1764917265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01687-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01687-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In accordance with institutional guidelines, this study was approved by the St John\u2019s Medical College Institutional ethical research board. Given the retrospective nature of the study, a waiver of informed consent was granted by the ethics committee. However, patient confidentiality and data anonymity were strictly maintained throughout the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"299"}}